Program
Bevacizumab
Also written as “bevacizumab”, “bevacizumab [Avastin]” and “Avastin (bevacizumab)”.
Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Ovarian Neoplasms · Carcinoma, Hepatocellular, led by 35 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 1217 open or running | phase 4since Jun 20, 2005 | Oct 16, 2002 | Nov 30, 2026phase 3 · NCT03148418 |
| Fresenius Kabi | 60 open or running | phase 3since Sep 19, 2017 | Feb 14, 2014 | none ahead |
| AstraZeneca | 54 open or running | phase 3since Nov 28, 2018 | Nov 28, 2018 | none ahead |
| Outlook Therapeutics | 51 open or running | phase 3since Feb 6, 2019 | Feb 6, 2019 | Dec 2027phase 3 · NCT05112861 |
| Pfizer | 50 open or running | phase 3since Jan 12, 2005 | Jan 12, 2005 | none ahead |
| Otsuka | 40 open or running | phase 3since Jan 29, 2021 | Dec 5, 2007 | none ahead |
| Biocad | 30 open or running | phase 3since Dec 27, 2012 | Dec 27, 2012 | none ahead |
| Innovent Biologics | 30 open or running | phase 3since Oct 23, 2016 | Oct 23, 2016 | none ahead |
| ago-research-gmbh | 20 open or running | phase 3since Apr 16, 2013 | Apr 16, 2013 | none ahead |
| GlaxoSmithKline | 21 open or running | phase 2since Oct 10, 2017 | Oct 10, 2017 | Jun 21, 2027phase 2 · NCT06796907 |
| navifus-corporation | 20 open or running | phase 2since Mar 19, 2024 | Jun 16, 2020 | none ahead |
| oncolytics-biotech | 21 open or running | phase 2since Feb 25, 2026 | Jan 7, 2011 | Aug 30, 2027phase 2 · NCT07446322 |
| ppd-development-lp | 22 open or running | phase 2since Nov 20, 2024 | Nov 20, 2024 | Jul 2028phase 2 · NCT06703073 |
| Sinopharm | 20 open or running | phase 3since Mar 22, 2022 | Oct 21, 2019 | none ahead |
| aryogen-pharmed-co | 10 open or running | phase 3since Sep 18, 2017 | Sep 18, 2017 | none ahead |
| Bio-Thera Solutions | 11 open or running | phase 3since Sep 21, 2023 | Sep 21, 2023 | none ahead |
| bradmer-pharmaceuticals-inc | 10 open or running | phase 2since May 19, 2009 | May 19, 2009 | none ahead |
| centus-biotherapeutics-limited | 10 open or running | phase 3since Jun 3, 2016 | Jun 3, 2016 | none ahead |
| Corcept Therapeutics | 11 open or running | phase 2since Apr 1, 2025 | Apr 1, 2025 | Dec 2027phase 2 · NCT06906341 |
| geron-corporation | 10 open or running | phase 2since Dec 2, 2010 | Dec 2, 2010 | none ahead |
| gradalis-inc | 10 open or running | phase 2since Mar 1, 2012 | Mar 1, 2012 | none ahead |
| iOMEDICO | 10 open or running | phase 4since Aug 28, 2014 | Aug 28, 2014 | none ahead |
| Jeil Pharmaceutical | 11 open or running | phase 2since Jan 12, 2026 | Jan 12, 2026 | Dec 31, 2029phase 2 · NCT07370818 |
| Johnson & Johnson | 10 open or running | phase 2since Jun 12, 2008 | Jun 12, 2008 | none ahead |
| laboratorio-elea-phoenix-s-a | 10 open or running | phase 3since Sep 4, 2018 | Sep 4, 2018 | none ahead |
| Laboratorios Sophia S.A de C.V. | 10 open or running | phase 3since Jan 19, 2022 | Jan 19, 2022 | none ahead |
| laboratorios-richmond-s-a-c-i-f | 10 open or running | phase 1since Apr 15, 2019 | Apr 15, 2019 | none ahead |
| mabscale-llc | 11 open or running | phase 3since Dec 8, 2022 | Dec 8, 2022 | Dec 2026phase 3 · NCT05654454 |
| Merck | 10 open or running | phase 3since Jul 1, 2020 | Jul 1, 2020 | none ahead |
| pharmatech | 10 open or running | phase 2since Oct 1, 2008 | Oct 1, 2008 | none ahead |
| prologue-research-international | 10 open or running | phase 3since Jun 5, 2003 | Jun 5, 2003 | none ahead |
| Sino Biopharmaceutical | 10 open or running | phase 1since Jul 18, 2022 | Jul 18, 2022 | none ahead |
| sirtex-medical | 10 open or running | phase 3since Aug 13, 2008 | Aug 13, 2008 | none ahead |
| the-emmes-company-llc | 10 open or running | phase 3since Oct 22, 2013 | Oct 22, 2013 | none ahead |
| xoft-inc | 10 open or running | phase 2since Dec 17, 2020 | Dec 17, 2020 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Gilead Sciences, Adagene, Tempest Therapeutics, NiKang Therapeutics, Immune-Onc Therapeutics, InflaRx, Edesa Biotech, Icad, Quintiles, FP Clinical Pharma S.R.L., Syngene, WuXi CDS Clinical Research (Shanghai), Libbs Farmacêutica LTDA and Sanofi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since May 9, 2017.
- Mar 22, 2022Phase 3 study in Non-squamous Non-small-cell Lung CancerSinopharm · NCT05318443 · 512 enrolled · China
- Jul 18, 2022Sino Biopharmaceutical’s first study: phase 1 study in Rectal NeoplasmsNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05476341 · 98 enrolled · China
- Dec 8, 2022mabscale-llc’s first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to mabscale-llcmabscale-llc · NCT05654454 · 620 planned · Russian Federation
- Mar 2, 2023Phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT05775159 · 294 enrolled · United States, China, Hong Kong and more
- Sep 11, 2023Phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT06040099 · 58 enrolled · United States
- Sep 21, 2023Bio-Thera Solutions’ first study: phase 3 study in Uterine Cervical NeoplasmsNew to Bio-Thera SolutionsBio-Thera Solutions · NCT06123884 · 526 planned · China
- Dec 19, 2023Phase 3 study in Macular DegenerationOutlook Therapeutics · NCT06190093 · 400 enrolled · United States
- Mar 19, 2024Phase 2 study in Glioblastomanavifus-corporation · NCT06329570 · 10 enrolled · United States
- Nov 20, 2024ppd-development-lp’s first studies: 2 phase 2 studies in Respiratory Distress SyndromeNew to ppd-development-lpppd-development-lp · NCT06703073, NCT06701656
- Jan 22, 2025Phase 2 study in NeoplasmsGlaxoSmithKline · NCT06796907 · 305 planned · United States, Argentina, Australia and more
- Apr 1, 2025Corcept Therapeutics’ first study: phase 2 study in Ovarian NeoplasmsNew to Corcept TherapeuticsCorcept Therapeutics · NCT06906341 · 270 planned · United States, Belgium, France and more
- Jan 12, 2026Jeil Pharmaceutical’s first study: phase 2 study in Ovarian NeoplasmsNew to Jeil PharmaceuticalJeil Pharmaceutical · NCT07370818 · 81 planned · South Korea
- Feb 25, 2026Phase 2 study in Ras-mutated Metastatic Colorectal CancerPhase 2 reachedoncolytics-biotech · NCT07446322 · 60 planned · United States
- Nov 16, 2026Primary completion moved from 2026-08 to 2027-12Date moved laterphase 2 · +16 months · NCT06906341
Ahead
- Nov 30, 2026Primary completion: phase 3 study in NeoplasmsHoffmann-La Roche · NCT03148418
- Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell Lungmabscale-llc · NCT05654454
- Jun 21, 2027Primary completion: phase 2 study in NeoplasmsGlaxoSmithKline · NCT06796907
- Jun 30, 2027Primary completion: phase 3 study in NeoplasmsHoffmann-La Roche · NCT05112965
TargetBeta
“A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine”NCIt, by rule
“Vascular endothelial growth factor A inhibitor”ChEMBL 37, by rule
Other programs on VEGFA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ranibizumabrule | Novartis | phase 4 | 108 |
| afliberceptrule | Regeneron Pharmaceuticals | phase 4 | 89 |
| faricimabrule | Hoffmann-La Roche | phase 4 | 17 |
| ivonescimabrule | Akeso | phase 3 | 48 |
| pumitamig | BioNTech | phase 3 | 34 |
| tivunatamig | Pfizer | phase 3 | 15 |
| suvemcitugrule | Simcere Pharmaceutical Group | phase 3 | 6 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| surabgene lomparvovec | AbbVie | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
Studies
The newest 60 of 185 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07446322Ras-mutated Metastatic Colorectal Cancer · United States | 2 | Recruiting | oncolytics-biotech | Aug 30, 2027 | 60 |
| NCT07370818Ovarian Neoplasms · South Korea | 2 | Not yet recruiting | Jeil Pharmaceutical | Dec 31, 2029 | 81 |
| NCT06906341Ovarian Neoplasms · United States, Belgium, France and more | 2 | Recruiting | Corcept Therapeutics | Dec 2027 | 270 |
| NCT06796907Neoplasms · United States, Argentina, Australia and more | 2 | Recruiting | GlaxoSmithKline | Jun 21, 2027 | 305 |
| NCT06703073Respiratory Distress Syndrome · United States | 2 | Recruiting | ppd-development-lp | Jul 2028 | 600 |
| NCT06701656Respiratory Distress Syndrome · United States | 2 | Recruiting | ppd-development-lp | Jul 2028 | 200 |
| NCT06329570Glioblastoma · United States | 2 | Suspended | navifus-corporation | Dec 31, 2027 | 10 |
| NCT06190093Macular Degeneration · United States | 3 | Completed | Outlook Therapeutics | Nov 7, 2024 | 400 |
| NCT06123884Uterine Cervical Neoplasms · China | 3 | Recruiting | Bio-Thera Solutions | Sep 2026 | 526 |
| NCT06040099Carcinoma, Hepatocellular · United States | 2 | Active, not recruiting | AstraZeneca | Jun 30, 2026 | 58 |
| NCT05775159Carcinoma, Hepatocellular · United States, China, Hong Kong and more | 2 | Active, not recruiting | AstraZeneca | Oct 27, 2026 | 294 |
| NCT05654454Carcinoma, Non-Small-Cell Lung · Russian Federation | 3 | Recruiting | mabscale-llc | Dec 2026 | 620 |
| NCT05476341Rectal Neoplasms · China | 1 | Completed | Sino Biopharmaceutical | Aug 18, 2017 | 98 |
| NCT05318443Non-squamous Non-small-cell Lung Cancer · China | 3 | Completed | Sinopharm | Dec 26, 2022 | 512 |
| NCT05217680Diabetic Macular Edema · Mexico | 3 | Completed | Laboratorios Sophia S.A de C.V. | Aug 18, 2025 | 509 |
| NCT05112965Neoplasms · China | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 30, 2027 | 49 |
| NCT05112861Macular Degeneration · United States | 3 | Active, not recruiting | Outlook Therapeutics | Dec 2027 | 120 |
| NCT04929223Colorectal Neoplasms · United States, Australia, Canada and more | 1 | Recruiting | Hoffmann-La Roche | Aug 31, 2030 | 542 |
| NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Hoffmann-La Roche | Feb 28, 2028 | 176 |
| NCT04737187Colorectal Neoplasms · United States, Austria, Belgium and more | 3 | Completed | Otsuka | Jul 19, 2022 | 492 |
| NCT04732286Carcinoma, Hepatocellular · Spain | 3 | Terminated | Hoffmann-La Roche | Apr 26, 2024 | 100 |
| NCT04681677Glioblastoma · United States | 2 | Terminated | xoft-inc | Apr 24, 2024 | 12 |
| NCT04677504Biliary Tract Neoplasms · United States, China, Hong Kong and more | 2 | Completed | Hoffmann-La Roche | May 16, 2022 | 162 |
| NCT04524871Advanced Liver Cancers · United States, China, France and more | 2 | Active, not recruiting | Hoffmann-La Roche | Jul 30, 2027 | 518 |
| NCT04516278Macular Degeneration · United States | 3 | Completed | Outlook Therapeutics | Feb 10, 2021 | 197 |
| NCT04487067Carcinoma, Hepatocellular · Italy | 3 | Completed | Hoffmann-La Roche | Aug 13, 2024 | 152 |
| NCT04456699Colorectal Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Merck | Mar 27, 2023 | 335 |
| NCT04446416Glioblastoma · Taiwan | – | Completed | navifus-corporation | Sep 30, 2022 | 6 |
| NCT04426825Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Hoffmann-La Roche | Jan 19, 2022 | 23 |
| NCT04408989Healthy Volunteers · New Zealand | 1 | Completed | Fresenius Kabi | Aug 20, 2021 | 114 |
| NCT04238663Healthy Volunteers · Germany | 1 | Completed | Fresenius Kabi | Mar 17, 2020 | 115 |
| NCT04238650Healthy Volunteers · Japan | 1 | Completed | Fresenius Kabi | Dec 27, 2019 | 49 |
| NCT04135898Healthy Male · China | 1 | Completed | Sinopharm | Mar 16, 2020 | 88 |
| NCT04325698Advanced Non-squamous NSCLC · China | 3 | Terminated | Pfizer | May 10, 2021 | 8 |
| NCT04126044Pharmacokinetics · China | 1 | Withdrawn | Pfizer | Jul 10, 2021 | 0 |
| NCT04102098Carcinoma, Hepatocellular · United States, Australia, Austria and more | 3 | Completed | Hoffmann-La Roche | Oct 21, 2022 | 668 |
| NCT04091217Melanoma · China | 2 | Completed | Hoffmann-La Roche | Aug 31, 2022 | 43 |
| NCT04068610Colonic Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | AstraZeneca | Oct 10, 2022 | 61 |
| NCT03919448Pharmacokinetics · Argentina | 1 | Completed | laboratorios-richmond-s-a-c-i-f | Sep 11, 2019 | 112 |
| NCT03847428Carcinoma, Hepatocellular · United States, Australia, Austria and more | 3 | Completed | AstraZeneca | May 15, 2026 | 908 |
| NCT03844074Macular Degeneration · Australia | 3 | Completed | Outlook Therapeutics | Jul 23, 2020 | 61 |
| NCT03834753Macular Degeneration · United States | 3 | Completed | Outlook Therapeutics | Jun 7, 2021 | 228 |
| NCT03794440Carcinoma, Hepatocellular · China | 3 | UNKNOWN | Innovent Biologics | Dec 2022 | 595 |
| NCT03778957Carcinoma, Hepatocellular · United States, Australia, Brazil and more | 3 | Active, not recruiting | AstraZeneca | Sep 11, 2023 | 724 |
| NCT03690739Ovarian Neoplasms · Germany | 3 | Terminated | ago-research-gmbh | Mar 3, 2021 | 9 |
| NCT03693573Carcinoma, Renal Cell | 3 | Withdrawn | Hoffmann-La Roche | Aug 14, 2021 | 0 |
| NCT03668054Macular Degeneration · Argentina | 3 | Completed | laboratorio-elea-phoenix-s-a | May 30, 2018 | 22 |
| NCT03635489Ovarian Neoplasms · China | 3 | Completed | Hoffmann-La Roche | May 26, 2021 | 100 |
| NCT03555149Colorectal Neoplasms · United States, Australia, France and more | 2 | Terminated | Hoffmann-La Roche | Sep 26, 2022 | 96 |
| NCT03434379Carcinoma, Hepatocellular · United States, Australia, Canada and more | 3 | Completed | Hoffmann-La Roche | Aug 31, 2020 | 558 |
| NCT03424005Breast Neoplasms · United States, Australia, France and more | 2 | Recruiting | Hoffmann-La Roche | Sep 30, 2030 | 1,132 |
| NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Terminated | Hoffmann-La Roche | Oct 14, 2025 | 314 |
| NCT03326193Ovarian Neoplasms · United States | 2 | Completed | GlaxoSmithKline | Dec 24, 2020 | 105 |
| NCT03296163Carcinoma, Non-Small-Cell Lung · Brazil, Bulgaria, Chile and more | 3 | Completed | Fresenius Kabi | Jul 3, 2019 | 627 |
| NCT03288987Colorectal Neoplasms · Iran, Islamic Republic of | 3 | Completed | aryogen-pharmed-co | Jul 30, 2018 | 126 |
| NCT03293654Healthy Volunteers · United Kingdom | 1 | Completed | Fresenius Kabi | May 29, 2019 | 114 |
| NCT03280563Breast Neoplasms · United States, Israel, South Korea | 2 | Completed | Hoffmann-La Roche | Sep 26, 2024 | 144 |
| NCT03193190Pancreatic Adenocarcinoma · United States, Germany, Japan and more | 2 | Completed | Hoffmann-La Roche | Feb 27, 2025 | 341 |
| NCT03178552Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 30, 2027 | 1,000 |
| NCT03148418Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Hoffmann-La Roche | Nov 30, 2026 | 382 |
How it is read
Names in the registry
- “Bevacizumab”, 133 entries
- “bevacizumab”, 31 entries
- “bevacizumab [Avastin]”, 20 entries
- “Avastin (bevacizumab)”, 6 entries
- “Utidelone combined with Bevacizumab”, 3 entries
Codes read as this program: MB02.
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 51 studies
- Carcinoma, Non-Small-Cell Lung, 34 studies
- Breast Neoplasms, 27 studies
- Ovarian Neoplasms, 26 studies
- Carcinoma, Hepatocellular, 13 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.